A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma

por Gressin, Rémy, Daguindau, Nicolas, Tempescul, Adrian, Moreau, Anne, Carras, Sylvain, Tchernonog, Emmanuelle, Schmitt, Anna, Houot, Roch, Dartigeas, Caroline, Pignon, Jean Michel, Corm, Selim, Banos, Anne, Mounier, Christiane, Dupuis, Jehan, Macro, Margaret, Fleury, Joel, Jardin, Fabrice, Sarkozy, Clementine, Damaj, Ghandi, Feugier, Pierre, Fornecker, Luc Matthieu, Chabrot, Cecile, Dorvaux, Veronique, Bouadallah, Krimo, Amorin, Sandy, Garidi, Reda, Voillat, Laurent, Joly, Bertrand, Celigny, Philippe Solal, Morineau, Nadine, Moles, Marie Pierre, Zerazhi, Hacene, Fontan, Jean, Arkam, Yazid, Alexis, Magda, Delwail, Vincent, Vilque, Jean Pierre, Ysebaert, Loic, Le Gouill, Steven, Callanan, Mary B.
Publicado 2019